FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab) Merck.com FDA OKs New Keytruda Shot for Cancer The New York Times FDA Approves Subcutaneous Pembrolizumab for Solid Tumors OncLive US FDA approves Merck’s injectable version of blockbuster cancer therapy Keytruda Reuters Merck wins approval of subcutaneous Keytruda, in bid to …
Read More »Tag Archives: Merck.com
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer – Merck.com
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer Merck.com FDA OKs New Keytruda Shot for Cancer The New York Times Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications OncLive Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial …
Read More »Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial – Merck.com
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial Merck.comView Full Coverage on Google News Source link
Read More »Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer – Merck.com
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer Merck.comView Full Coverage on Google News Source link
Read More »